IP Library Granted Patent US 9,616,116
Granted Patent B2
US 9,616,116 · App. 14/636,951 · Granted Apr 11, 2017

Detoxified endotoxin immunogenic compositions and uses thereof

Inventors: Alan S. Cross (Chevy Chase, MD); Apurba K. Bhattacharjee (Kensington, MD); Wendell D. Zollinger (Leahi, UT); Steven M. Opal (Barrington, RI)
Assignees: UNIVERSITY OF MARYLAND, BALTIMORE; THE MEMORIAL HOSPITAL OF RHODE ISLAND; UNITED STATES ARMY
A61K39/0258A61K39/095A61K2039/55561A61K2039/55583A61K2039/58A61K2039/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,616,116
App. No.
14/636,951
Granted
Apr 11, 2017
Kind
B2
Abstract

The present invention provides an immunogenic composition of a lipopolysaccharide vaccine and a non-alum adjuvant. The immunogenic composition may be detoxified J5 core lipopolysaccharide of Escherichia coli non-covalently complexed with group B meningococcal outermembrane protein. Also provided are methods for preventing an infection caused by a Gram-negative bacteria in an individual via administering the immunogenic compositions to the individual.

Claims (7)

1. An immunogenic composition, consisting of:

a detoxified E. coli J5 core lipopolysaccharide of the Rc chemotype, non-covalently complexed with group B meningococcal outer membrane protein; and

CpG 7909.

2. A method of actively immunizing an individual against infection by a heterologous Gram negative bacterium comprising administering to the individual an immunologically effective amount of the immunogenic composition of claim 1 .

3. The method of claim 2 , wherein the immunogenic composition is administered subcutaneously, intramuscularly, or intranasally.

4. The method of claim 2 , wherein the detoxified E. coli J5 core lipopolysaccharide non-covalently complexed with the group B meningococcal outer membrane protein is present in the immunogenic composition in a concentration of 5 to 50 micrograms and the CpG 7909 is present in the immunogenic composition in a concentration of 250 to 500 micrograms.

5. The method of claim 2 , wherein the immunogenic composition elicits anti-J5 core lipopolysaccharide antibodies in the individual that bind to the heterologous Gram negative bacterium.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 22, 2015
From: UNIVERSITY OF MARYLAND BALTIMORE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035874/0487 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2015
From: CROSS, ALAN
To: UNIVERSITY OF MARYLAND, BALTIMORE
Reel/Frame 035307/0849 →
Continuity (3)
Continuation In Part 12083993
Provisional Application 60729570 · Oct 24, 2005
Related Publication 20150174228A1 · Jun 25, 2015